Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced today that it is releasing a course on Disease Modeling and Target Identification, available for ...

Drug development is a complex and time-consuming endeavor that traditionally relies on the experience of drug developers and trial-and-error experimentation. The ...

Pediatric drug development faces significant challenges, including underfunding, ethical concerns, and complex regulatory frameworks. Despite significant advances in adult drug development, children ...

An online course on Disease Modeling and Target Discovery launched 7 months ago by clinical stage generative artificial intelligence (AI)-driven biotechnology company Insilico Medicine has surpassed 2 ...

The most striking evidence that artificial intelligence can provide profound scientific breakthroughs came with the unveiling of a program called AlphaFold by Google DeepMind. In 2016 researchers at ...

A robotic arm slowly approached a glass vial (vial) the size of a finger. It paused as if gauging the position, then firmly gripped the cap. Instead of the robotic arm, the base holding the vial began ...

Identifying and accelerating drug development is big business. The costs in this industry are significant and finding pathways to optimize using AI methods is top of mind in this fast and evolving ...

Our Phase 2 design reflects both the translational science and the realities of ALS by integrating validated biomarkers such as neurofilament light chain alongside clinically meaningful endpoints,” ...

Short-Term Surgical Mission in Sub-Saharan Country, Experience of a Breast-Dedicated Team: Reviewing the Past and Stepping Toward the Last Mission Rapidly expanding systemic treatment options, ...